Trial Profile
A Randomized, Open-label, Multicenter, Phase 1b/2 Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Hyaluronidase (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc
- 25 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 26 Feb 2019 Planned primary completion date changed from 9 May 2019 to 28 Jun 2019.
- 04 Feb 2019 Planned End Date changed from 9 May 2019 to 28 Jun 2019.